Novavax sees weak Covid vaccine sales
The Gazette on MSN10d
Three years and waiting for Canada's made-in-Montreal COVID shotVaccine production is nearly three years behind schedule at a federally owned plant in Montreal and the future of a deal ...
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
17d
Health officials say eligible residents can receive the COVID-19 vaccine at the same time as or at any time before or after ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.
Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it has filed for authorization with Health Canada for its 2024-2025 ...
Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...
TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback